Our findings that two TOP2A-amplified CTCs come from HER2- primary tumors and that the HER2 gene is not co-amplified in these CTCs are consistent with previous observations described in primary BC tissues [37,38]. The gene discussed is ERBB2; the disease is breast cancer.